Plain-English translation of NCT07565506 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is an early-stage trial testing Bisphosphocin® Nu-3 gel, a new topical treatment designed to fight infections in diabetic foot ulcers. The study will evaluate whether the medication is safe and effective when applied twice daily at three different strengths (2%, 5%, and 10%) over 14 days. You would be assigned randomly to receive one of these three doses and monitored to see how well the treatment works and whether you experience any side effects.
Diabetic foot ulcers that become infected can be serious and difficult to treat, sometimes leading to complications or loss of limb. This medication is being tested to see if it offers a new, effective way to fight these infections while being safe and well-tolerated by patients.
You likely qualify if…
You likely don't qualify if…
You would visit the study site for a screening appointment where doctors confirm your ulcer qualifies, then start treatment at a baseline visit the next day. For 14 days, you (or your caregiver) would apply the gel to your ulcer twice daily and cover it with special dressings. You would have follow-up visits during and after treatment to allow doctors to check how your ulcer is healing and whether you're having any side effects. The entire study takes a few weeks from start to finish.
AI-generated summary from trial data · Sep 20, 2026 · Not medical advice
United States